PE20151779A1 - Xantinas sustituidas y metodos de uso de las mismas - Google Patents
Xantinas sustituidas y metodos de uso de las mismasInfo
- Publication number
- PE20151779A1 PE20151779A1 PE2015001829A PE2015001829A PE20151779A1 PE 20151779 A1 PE20151779 A1 PE 20151779A1 PE 2015001829 A PE2015001829 A PE 2015001829A PE 2015001829 A PE2015001829 A PE 2015001829A PE 20151779 A1 PE20151779 A1 PE 20151779A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- methods
- substituted xanthines
- refers
- xanthines
- Prior art date
Links
- 229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 title 1
- 102000003621 TRPC5 Human genes 0.000 abstract 1
- 101150042815 TRPC5 gene Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 230000001052 transient effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Silver Salt Photography Or Processing Solution Therefor (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361789724P | 2013-03-15 | 2013-03-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20151779A1 true PE20151779A1 (es) | 2015-11-20 |
Family
ID=50680155
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2015001829A PE20151779A1 (es) | 2013-03-15 | 2014-03-14 | Xantinas sustituidas y metodos de uso de las mismas |
Country Status (31)
| Country | Link |
|---|---|
| US (7) | US9359359B2 (enExample) |
| EP (1) | EP2970303B3 (enExample) |
| JP (1) | JP6360149B2 (enExample) |
| KR (1) | KR102227629B1 (enExample) |
| CN (2) | CN107082782B (enExample) |
| AU (1) | AU2014228206C1 (enExample) |
| CA (1) | CA2899646C (enExample) |
| CL (1) | CL2015002738A1 (enExample) |
| CY (1) | CY1119042T1 (enExample) |
| DK (1) | DK2970303T6 (enExample) |
| EA (1) | EA028815B1 (enExample) |
| ES (1) | ES2636835T7 (enExample) |
| HR (1) | HRP20170840T4 (enExample) |
| HU (1) | HUE033528T4 (enExample) |
| IL (1) | IL240216B (enExample) |
| LT (1) | LT2970303T (enExample) |
| MX (1) | MX370372B (enExample) |
| MY (1) | MY189912A (enExample) |
| NZ (1) | NZ711718A (enExample) |
| PE (1) | PE20151779A1 (enExample) |
| PH (1) | PH12015502141B1 (enExample) |
| PL (1) | PL2970303T6 (enExample) |
| PT (1) | PT2970303T (enExample) |
| RS (1) | RS56066B2 (enExample) |
| SG (1) | SG11201506479TA (enExample) |
| SI (1) | SI2970303T1 (enExample) |
| TW (1) | TWI609867B (enExample) |
| UA (1) | UA117470C2 (enExample) |
| UY (1) | UY35488A (enExample) |
| WO (1) | WO2014143799A2 (enExample) |
| ZA (1) | ZA201505414B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8173750B2 (en) | 2009-04-23 | 2012-05-08 | ATRP Solutions, Inc. | Star macromolecules for personal and home care |
| DK2970303T6 (en) | 2013-03-15 | 2018-10-08 | Hydra Biosciences Inc | SUBSTITUTED XANTHINES AND PROCEDURES FOR USING IT |
| JP6667092B2 (ja) * | 2014-08-11 | 2020-03-18 | ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ， ＬＬＣ | ピロロ［３，２−ｄ］ピリミジン−２，４（３Ｈ，５Ｈ）−ジオン誘導体 |
| WO2016159746A1 (en) | 2015-03-27 | 2016-10-06 | Latvian Institute Of Organic Synthesis | Novel ethynylxanthines, their preparation and use as inhibitors of matrix metalloproteinases and angiogenesis |
| WO2016159747A1 (en) | 2015-03-27 | 2016-10-06 | Latvian Institute Of Organic Synthesis | Ethynylxanthines, preparation and use as calcium ion channel modulators |
| WO2016159745A1 (en) | 2015-03-27 | 2016-10-06 | Latvian Institute Of Organic Synthesis | Ethynylxanthines, preparation and use for cancer treatment |
| DK3280417T3 (da) * | 2015-04-08 | 2020-11-02 | Lewis And Clark Pharmaceuticals Inc | Xanthin-substitueret alkynyl karbamater/omvendte karbamater som a2b antagonister |
| CN107118586A (zh) * | 2016-02-24 | 2017-09-01 | 中国科学技术大学 | 含氮杂环基取代的烯类化合物的用途 |
| GB201702160D0 (en) | 2017-02-09 | 2017-03-29 | Univ Leeds Innovations Ltd | Inhibitors for use in therapy |
| US11666577B2 (en) * | 2017-02-28 | 2023-06-06 | National Institute Of Biological Sciences, Beijing | MLKL inhibitors |
| WO2018157800A1 (en) * | 2017-02-28 | 2018-09-07 | National Institute Of Biological Sciences, Beijing | Mlkl inhibitors |
| PL3652176T3 (pl) * | 2017-07-11 | 2022-04-04 | Boehringer Ingelheim International Gmbh | Podstawione pochodne ksantyny |
| EP3761989A4 (en) * | 2018-03-05 | 2021-11-24 | Goldfinch Bio, Inc. | IMIDAZODIAZEPINEDIONE AND METHOD OF USE THEREOF |
| AU2019396499B2 (en) * | 2018-12-12 | 2024-10-10 | Boehringer Ingelheim International Gmbh | Substituted xanthine derivatives |
| EP3894409B1 (en) | 2018-12-12 | 2023-08-23 | Boehringer Ingelheim International GmbH | Substituted xanthine derivatives |
| CN112979651B (zh) * | 2021-04-09 | 2022-02-01 | 南京纽邦生物科技有限公司 | 一种副黄嘌呤的制备方法 |
| CN113354646B (zh) * | 2021-07-06 | 2022-11-15 | 南开大学 | 8-芳氧基烷氧基取代黄嘌呤衍生物及其制备方法和应用 |
| CN115636831B (zh) * | 2022-10-27 | 2024-11-08 | 中国药科大学 | 稠合嘧啶二酮类化合物、其用途以及药物组合物 |
| WO2024133476A1 (en) | 2022-12-20 | 2024-06-27 | Boehringer Ingelheim International Gmbh | Process for the preparation of 7-(4-chlorobenzyl)-1-(3-hydroxypropyl)-3-methyl-8-(3-(trifluoromethoxy)-phenoxy)-3,7-dihydro-1h-purine-2,6-dione |
| WO2024153028A1 (zh) * | 2023-01-20 | 2024-07-25 | 深圳晶蛋生物医药科技有限公司 | 大环类化合物、其药物组合物及其应用 |
| WO2024165540A1 (en) | 2023-02-06 | 2024-08-15 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising 7-(4-chlorobenzyl)-1-(3-hydroxypropyl)-3-methyl-8-(3-(trifluoromethoxy)-phenoxy)-3,7-dihydro-1h-purine-2,6-dione |
| CN118459461A (zh) | 2023-02-08 | 2024-08-09 | 中国科学院上海药物研究所 | 黄嘌呤类化合物及其用途 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4304650A1 (de) * | 1993-02-16 | 1994-08-18 | Thomae Gmbh Dr K | Kondensierte 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| US6878715B1 (en) * | 1994-02-18 | 2005-04-12 | Cell Therapeutics, Inc. | Therapeutic compounds for inhibiting interleukin-12 signals and method for using same |
| JP4191269B2 (ja) | 1996-05-17 | 2008-12-03 | 興和株式会社 | 新規なアニリド化合物及びこれを含有する医薬 |
| JPH10318487A (ja) | 1997-05-16 | 1998-12-04 | Mitsubishi Gas Chem Co Inc | 真空断熱材用ゲッタ |
| US6075029A (en) * | 1998-01-02 | 2000-06-13 | Cell Therapeutics, Inc. | Xanthine modulators of metabolism of cellular P-450 |
| US6187780B1 (en) * | 1998-04-16 | 2001-02-13 | Boehringer Ingelheim Pharma Kg | Assymetrically substituted xanthine derivatives having adenosine A1 antagonistic activity |
| JP2002541258A (ja) * | 1999-04-09 | 2002-12-03 | セル セラピューティクス インコーポレーテッド | インターリューキン−１２シグナルを阻害するための治療用化合物及びその使用方法 |
| ES2244634T3 (es) * | 2000-07-04 | 2005-12-16 | Novo Nordisk A/S | Purina-2,6-dionas como inhibidoras de la enzima dipeptidil peptidasa iv (ddp-iv). |
| AU2002239508B9 (en) | 2000-12-07 | 2005-09-08 | Gilead Palo Alto, Inc. | Substituted 1, 3, 5-triazines and pyrimidines as ABCA-1 elevating compounds against coronary artery disease or atherosclerosis |
| HU230384B1 (hu) * | 2001-02-24 | 2016-03-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xantinszármazékok, előállításuk és alkalmazásuk gyógyszerként |
| NZ532816A (en) * | 2001-11-09 | 2005-11-25 | Cv Therapeutics Inc | A2B adenosine receptor antagonists |
| MXPA05011860A (es) * | 2003-05-06 | 2006-02-17 | Cv Therapeutics Inc | Derivados de xantina como antagonistas del receptor de adenosina a2b. |
| CA2545944A1 (en) | 2003-11-13 | 2005-06-02 | Board Of Regents, The University Of Texas System | Inhibition of trp channels as a treatment for cardiac hypertrophy and heart failure |
| US7393827B2 (en) | 2004-12-30 | 2008-07-01 | Diakine Therapeutics, Inc. | Pharmaceutical compositions and methods for restoring β-cell mass and function |
| US8143254B2 (en) | 2005-02-18 | 2012-03-27 | Cornell Research Foundation, Inc. | Methods for modulating ion channels |
| EP1912992A1 (en) * | 2005-08-10 | 2008-04-23 | SmithKline Beecham Corporation | Xanthine derivatives as selective hm74a agonists |
| ATE459620T1 (de) | 2005-09-06 | 2010-03-15 | Glaxosmithkline Llc | Benzimidazolthiophenverbindungen als plk- modulatoren |
| CA2631885A1 (en) | 2005-12-07 | 2007-06-14 | Ucb Pharma, S.A. | Xanthine derivatives, processes for preparing them and their uses |
| CN101384261B (zh) * | 2005-12-22 | 2011-12-07 | 海德拉生物科学公司 | 治疗疼痛的组合物 |
| US20070232673A1 (en) | 2006-01-19 | 2007-10-04 | Roth Gregory P | 2-Imino-benzimidazoles |
| WO2007101213A2 (en) | 2006-02-28 | 2007-09-07 | Kalypsys, Inc. | Novel 2-oxo-1,2,3,4-tetrahydropyrimidines, bicyclic pyrimidine diones and imidazolidine-2,4-diones useful as inducible nitric oxide synthase inhibitors |
| WO2008011518A2 (en) * | 2006-07-19 | 2008-01-24 | Diakine Therapeutics, Inc. | Encapsulation system |
| WO2009157938A1 (en) * | 2008-06-26 | 2009-12-30 | Cv Therapeutics, Inc. | A2b adenosine receptor antagonists for treating cancer |
| US20120148604A1 (en) | 2009-08-20 | 2012-06-14 | Transposagen Biopharmaceuticals, Inc. | Trp inhibitors and uses thereof |
| WO2011114184A1 (en) * | 2010-03-15 | 2011-09-22 | Glenmark Pharmaceuticals S.A. | Amides of heterocyclic compounds as trpa1 inhibitors |
| US9260430B2 (en) | 2010-06-08 | 2016-02-16 | Hydra Biosciences, Inc. | Use of TRPA1 antagonists to prevent or treat infections caused by biological-warfare agents |
| JP2013023102A (ja) | 2011-07-22 | 2013-02-04 | Panasonic Corp | 列車情報提供システム |
| BR112014002960A2 (pt) * | 2011-08-09 | 2017-02-21 | Cubist Pharm Inc | inibição de canal de íons potencial receptor transiente trpa1 |
| CN103121970B (zh) | 2012-12-04 | 2015-04-29 | 中国科学院昆明植物研究所 | 苯并咪唑及其衍生物，其药物组合物及其在制备抗抑郁药物中的应用 |
| DK2970303T6 (en) | 2013-03-15 | 2018-10-08 | Hydra Biosciences Inc | SUBSTITUTED XANTHINES AND PROCEDURES FOR USING IT |
-
2014
- 2014-03-14 DK DK14722452.1T patent/DK2970303T6/en active
- 2014-03-14 SI SI201430241T patent/SI2970303T1/sl unknown
- 2014-03-14 HR HRP20170840TT patent/HRP20170840T4/hr unknown
- 2014-03-14 KR KR1020157029667A patent/KR102227629B1/ko active Active
- 2014-03-14 CA CA2899646A patent/CA2899646C/en active Active
- 2014-03-14 RS RS20170566A patent/RS56066B2/sr unknown
- 2014-03-14 WO PCT/US2014/027920 patent/WO2014143799A2/en not_active Ceased
- 2014-03-14 EP EP14722452.1A patent/EP2970303B3/en active Active
- 2014-03-14 CN CN201710063554.XA patent/CN107082782B/zh active Active
- 2014-03-14 NZ NZ711718A patent/NZ711718A/en unknown
- 2014-03-14 PL PL14722452T patent/PL2970303T6/pl unknown
- 2014-03-14 HU HUE14722452A patent/HUE033528T4/en unknown
- 2014-03-14 TW TW103109651A patent/TWI609867B/zh active
- 2014-03-14 PT PT147224521T patent/PT2970303T/pt unknown
- 2014-03-14 SG SG11201506479TA patent/SG11201506479TA/en unknown
- 2014-03-14 CN CN201480023267.0A patent/CN105143229B/zh active Active
- 2014-03-14 MY MYPI2015702631A patent/MY189912A/en unknown
- 2014-03-14 ES ES14722452.1T patent/ES2636835T7/es active Active
- 2014-03-14 JP JP2016502662A patent/JP6360149B2/ja active Active
- 2014-03-14 AU AU2014228206A patent/AU2014228206C1/en active Active
- 2014-03-14 US US14/210,781 patent/US9359359B2/en active Active
- 2014-03-14 LT LTEP14722452.1T patent/LT2970303T/lt unknown
- 2014-03-14 UA UAA201507774A patent/UA117470C2/uk unknown
- 2014-03-14 PE PE2015001829A patent/PE20151779A1/es active IP Right Grant
- 2014-03-14 EA EA201591615A patent/EA028815B1/ru not_active IP Right Cessation
- 2014-03-14 MX MX2015011617A patent/MX370372B/es active IP Right Grant
- 2014-03-17 UY UY0001035488A patent/UY35488A/es active IP Right Grant
-
2015
- 2015-07-28 ZA ZA2015/05414A patent/ZA201505414B/en unknown
- 2015-07-29 IL IL240216A patent/IL240216B/en active IP Right Grant
- 2015-09-15 CL CL2015002738A patent/CL2015002738A1/es unknown
- 2015-09-15 PH PH12015502141A patent/PH12015502141B1/en unknown
-
2016
- 2016-04-25 US US15/137,327 patent/US20160237089A1/en not_active Abandoned
-
2017
- 2017-06-14 US US15/622,838 patent/US9969736B2/en active Active
- 2017-06-20 CY CY20171100647T patent/CY1119042T1/el unknown
-
2018
- 2018-05-02 US US15/968,941 patent/US10399982B2/en active Active
-
2019
- 2019-04-29 US US16/397,697 patent/US11208409B2/en active Active
-
2021
- 2021-11-10 US US17/523,838 patent/US11958854B2/en active Active
-
2024
- 2024-02-21 US US18/583,293 patent/US20250034143A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20151779A1 (es) | Xantinas sustituidas y metodos de uso de las mismas | |
| CO2018004124A2 (es) | Compuestos heterocíclicos | |
| CL2018003323A1 (es) | Piridinas sustituidas con heteroarilo y métodos de uso. | |
| CU20180147A7 (es) | Compuestos de heteroarilo sustituido como moduladores de fxr (nr1h4) | |
| CR20160119A (es) | Nuevos compuestos y sus composiciones farmacéuticas para el tratamiento de la fibrosis quística | |
| UY35300A (es) | Formulación de combinación de dos compuestos antivirales | |
| MX364796B (es) | Moduladores de p2x7. | |
| CU20180144A7 (es) | Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos | |
| NI201400150A (es) | Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen. | |
| CL2019001458A1 (es) | Nuevos derivados de isoxazolil éter como pam de gaba a alfa5. | |
| GT201300153A (es) | Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)- n4-[2-(propan-2-sulfonil)-fenil pirimidim-2,4-diamina | |
| MX2016002571A (es) | Regulador de ph de transduccion. | |
| CL2016000925A1 (es) | Inhibidores de bromodominio | |
| CL2017001923A1 (es) | Derivados de 9h-pirrolo-dipiridina | |
| CR20150045A (es) | Inhibidores de hepatitis c | |
| CR20140275A (es) | Triazolopiridinas sustituidas | |
| CL2017000271A1 (es) | Derivados de pirimidina sustituidos con heterociclilo opcionalmente condensados útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias | |
| CL2015001377A1 (es) | Inhbibidores de bmi-1 primidinas sustituidas inversas | |
| MX2015009719A (es) | Inhibidores benzoquinolona de vmat2. | |
| CR20140135A (es) | Nuevos derivados de aril-quinolina | |
| CR20180143A (es) | Nuevos compuestos biciclicos como inhibidores duales de atx/ca | |
| SV2018005760A (es) | Derivados de aminotiazol utiles como agentes antiviricos | |
| DK3186372T3 (da) | Solubilisering af kommunalt fast affald (MSW) ved hjælp af en enzymblanding | |
| UY35410A (es) | Compuestos de piperidina sustituidos y su uso como moduladores de receptores de orexina | |
| CL2011002258A1 (es) | Compuestos derivados heterociclicos fusionados; composicion farmaceutica que los comprende; y uso de los compuestos para tratar vih. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |